Navigation Links
Researchers identify a novel therapeutic approach for liver cancer
Date:12/9/2011

BOSTON Cancer of the liver rare in the United States but the third-leading cause of cancer death worldwide can result from environmental exposures or infections like chronic hepatitis, but the link is poorly understood.

Now, researchers at Dana-Farber Cancer Institute have identified a mechanism in mice that triggers inflammation in the liver and transforms normal cells into cancerous ones. In addition, they demonstrated in a mouse model that a particular micro-RNA (miR-124) - a member of a recently discovered class of molecular regulators could be harnessed to treat or even prevent liver cancer.

"In this study we are describing for the first time a micro-RNA that is able to prevent and treat liver cancer," said Dimitrios Iliopoulos, of Dana-Farber's Department of Cancer Immunology and AIDS. The findings are being published today in the journal Cell.

The authors said they plan to start a phase I clinical trial using miR-124 in liver cancer patients in 2012.

Iliopoulos and his colleagues found that in mice given a carcinogenic chemical, DEN, liver cancer is initiated by the activation of a molecular circuit that sets up an inflammatory state in the cells, leading to cancer. Once this inflammatory circuit is turned on even for a few days, it becomes permanent, sustaining its activity through a never-ending feedback loop a "snowball effect," as Iliopoulos termed it.

Iliopoulos previously identified a similar feedback circuit implicated in the development of breast cancer.

One element of the circuit is a micro-RNA called miR-124, the Dana-Farber team reported.

Micro-RNAs are extremely short lengths of RNA a messenger molecule that helps the cell build proteins according to DNA instructions - which are not translated into proteins. MiRNAs have been recently implicated in the pathogenesis of human diseases including different types of cancer. The Dana-Farber team found that miR-124 and another key controller of the feedback circuit, HNF4α, showed reduced activity in the cancer cells.

HFN4α is an essential factor in formation of liver cells and their proper function. When HNF4α is suppressed, said Iliopoulos, it creates a temporary state of inflammation in the cell a forerunner of cancer. "After only a few days, this transient inflammatory response is converted into a chronic inflammatory response by this feedback circuit that is continuously amplified," he said.

Because HNF4α and miR-124 interact with each other, the scientists hypothesized that boosting activity of miR-124 might restore normal activity in HNF4α, halting the runaway inflammatory cycle and causing tumors to stop growing.

To test this notion they administered systemically miR-124 once a week for four weeks to mice that had developed liver cancer by exposure to DEN. "We found that miR-124 suppressed more than 80 per cent of tumor growth and size" by causing the cancer cells to self-destruct, the scientists wrote. They observed no toxic effects in other essential organs, such as the kidneys, spleen, heart and lungs.

Further, they showed that giving miR-124 to mice exposed to DEN actually prevented the development of liver tumors.

"Our hope is that miR-124 potentially could be used as a preventive in patients at high risk of liver cancer because they have chronic hepatitis C or as a therapeutic agent in patients with liver cancer" said Iliopoulos.


'/>"/>
Contact: Teresa Herbert
teresa_herbert@dfci.harvard.edu
617-632-5665
Dana-Farber Cancer Institute
Source:Eurekalert  

Related medicine news :

1. Researchers design Alzheimers antibodies
2. Toronto researchers obtain detailed molecular signature for Tankyrase
3. Danish mushroom inspires cancer researchers
4. Bone Drugs May Also Battle Breast Cancer, Researchers Say
5. Researchers discover that changes in bioelectric signals cause tadpoles to grow eyes in back, tail
6. UCLA researchers suggest unconventional approach to control HIV epidemics
7. Mayo Clinic researchers find drug duo kills chemotherapy-resistant ovarian cancer cells
8. Researchers discover patterns of genes associated with timing of breast cancer recurrences
9. University of Kentucky researchers awarded CDC grant to study cancer survival in Appalachia
10. Moffitt researchers will be strong participants in American Society of Hematology meeting
11. Moffitt Cancer Center researchers find MK1775 active against sarcomas
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Researchers identify a novel therapeutic approach for liver cancer
(Date:5/5/2016)... ... May 05, 2016 , ... An essential tool for ... and certain Canadian provinces is now available from the International Association of Industrial ... , The report, Workers’ Compensation Laws as of January 1, 2016, ...
(Date:5/5/2016)... ... 05, 2016 , ... Tim Dieter has announced the latest ... Dubuque, IA. The current campaign fundraises for Veteran’s Freedom Center on behalf of ... Freedom Center may now be made here: http://www.veteransfreedomcenter.com/donate/ . , Veteran’s Freedom ...
(Date:5/5/2016)... ... ... Dr. Benjamin Stong of Kalos Facial Plastic Surgery, LLC in Atlanta, Georgia proudly ... certified and the only facial plastic surgeon in Atlanta to offer Micro-droplet Fat ... stem cells can be used to provide stabilization to hair transplant results or they ...
(Date:5/5/2016)... York) , ... (PRWEB) May 05, 2016 , ... ... talent acquisition startup, HireNurses, on the eve of National Nurses Week (May ... nurses and healthcare employers. With their enrollment into the Talent Tech Lab Virtual Incubation ...
(Date:5/5/2016)... Rochester, NY (PRWEB) , ... May 05, 2016 ... ... app is now available for iOS and Android devices. VisualDx is the ... expanded to include diagnostic support across general medicine. The system speeds diagnosis, ...
Breaking Medicine News(10 mins):
(Date:5/5/2016)... 2016 Research and ... Systemic Lupus Erythematosus Market and Competitive Landscape ...      (Logo: http://photos.prnewswire.com/prnh/20160330/349511LOGO ... Systemic Lupus Erythematosus Market and Competitive Landscape ... Systemic Lupus Erythematosus pipeline products, Systemic Lupus ...
(Date:5/4/2016)... Israel , May 4, 2016 ... that BiondVax,s CEO, Dr. Ron Babecoff , will be ... New York City . On Thursday, May ... 2016, a conference presented by Joseph Gunner & ... The BiondVax presentation that Dr. Babecoff will be using ...
(Date:5/4/2016)... New Jersey , May 4, 2016 ... its successful completion of an alternative public offering (APO). ... wholly owned operating company, Valeritas, Inc. and a private ... common stock at $5.00 per share. Under ... on May 3, 2016, Valeritas Holdings, Inc. will trade ...
Breaking Medicine Technology: